Andrea Paul is a corporate partner at WilmerHale and a former biotech executive who provides strategic counsel on a wide range of corporate matters.

Andrea helps public and private companies in the life sciences and technology sectors navigate the legal complexities that come with growing and running their businesses. This includes counseling clients on the intricacies of U.S. securities laws, corporate governance, and public and private capital raising transactions. She also advises clients on collaborations, licensing, clinical and commercial supply agreements, and other complex agreements.

Prior to joining WilmerHale, Andrea served as Chief Legal Officer and Corporate Secretary at Zentalis Pharmaceuticals, where she oversaw Legal, Quality and Information Technology. Before that, she was General Counsel and Corporate Secretary at LogicBio Therapeutics, and she held senior roles at Akebia Therapeutics and Momenta Pharmaceuticals. In these roles, she advised on significant transactions, including mergers and acquisitions, equity financings, royalty monetization, debt facilities, collaborations and supply agreements.

Andrea speaks on a variety of corporate matters, including U.S. securities laws, working with boards, and internal investigations.

Experience

  • STRATEGIC ADVISING

    • Trusted strategic advisor to boards and executives on a broad range of issues, including complex disclosure issues, capital raises, M&A, licensing/collaboration transactions, corporate governance, regulatory, alliance, supply chain, investigations and employment/compensation.
    • Led Legal, Corporate Secretary, Quality and IT functions at Zentalis Pharmaceuticals, led Legal and Corporate Secretary functions at LogicBio Therapeutics, and was a key member of the Legal teams at Akebia Therapeutics and Momenta Pharmaceuticals. 
    • Architect of SEC filings and disclosure strategy across multiple companies, including 10-Ks/20-Fs, 10-Qs, proxy statements, S-1s/F-1s, S-3s, S-4s, and 8-Ks.
    • Implemented legal training programs, contracting processes, publication review processes, contract management systems, and artificial intelligence (AI)-based tools.
  • FINANCINGS AND STRATEGIC TRANSACTIONS

    • Boston’s Museum of Science on its up to $7,000,000 tax-exempt bond financing
    • Zentalis Pharmaceuticals in its asset sale to Immunome
    • Zentalis Pharmaceuticals in its licensing/collaboration with Immunome
    • Zentalis Pharmaceuticals in its $250 million follow-on offering
    • Akebia Therapeutics in its licensing/collaboration with Vifor Pharma Group
    • Akebia Therapeutics in its $60 million royalty monetization with HealthCare Royalty Management
    • Akebia Therapeutics in its $100 million term loans with Pharmakon Advisors
    • Akebia Therapeutics in approximately $210 million of follow-on offerings
    • Akebia Therapeutics in its merger-of-equals with Keryx Biopharmaceuticals
    • G1 Therapeutics in its Series B and Series C financing rounds and its initial public offering
    • The underwriters in the initial public offering of Bavarian Nordic
    • OXiGENE in multiple follow-on offerings and a PIPE
    • NeuroMetrix in its approximately $13.6 million follow-on offering
    • Wellington Management Company in Mozido’s Series B financing round
    • Solectria Renewables in its sale to Yaskawa Electric
    • The underwriters in Stemline Therapeutics’ follow-on offering
    • AFT Pharmaceuticals in its initial public offering on the NZX and the ASX
    • Statoil Fuel & Retail on its approximately $920 million initial public offering on the Oslo Børs
    • Byggmax Group on its approximately $164 million initial public offering on Nasdaq Stockholm
    • Barclays Bank on over $12 billion of notes offerings
    • Statoil on nearly $5 billion of notes offerings
    • BP on over $3 billion of notes offerings
    • European Investment Bank on $3 billion of notes offerings 
    • Advised numerous biotech clients on a wide variety of agreements, including supply, translational and research agreements
    • Advised numerous life sciences clients on ATM facilities

    *Includes matters from prior to joining WilmerHale.

Insights & News

Credentials

  • Education

    • JD, Harvard Law School, 2008

      Managing Editor, Vol. 121 of The Harvard Law Review

      cum laude

    • BA, Art History, Columbia University, 2003

      summa cum laude

      Phi Beta Kappa 

      Senior Thesis Prize in Art History

  • Admissions

    • Massachusetts

    • New York

Credentials

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.